{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:17:59Z","timestamp":1744719479880},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,18]]},"DOI":"10.7759\/cureus.67161","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:50:57Z","timestamp":1724050257000},"source":"Crossref","is-referenced-by-count":1,"title":["Superiority of Avacopan and Mepolizumab to Glucocorticoid Tapering in the Treatment of Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Rishma","family":"Gattu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Demory Beckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806233182504","article-title":"Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis","volume":"318","author":"Falk RJ","year":"1988","unstructured":"Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988, 318:1651-7. 10.1056\/NEJM198806233182504","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.6.1888.1888","article-title":"Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase","volume":"74","author":"Niles JL","year":"1989","unstructured":"Niles JL, McCluskey RT, Ahmad MF, et al.. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood. 1989, 74:1888-93. 10.1182\/blood.V74.6.1888.1888","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(85)91147-x","article-title":"Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis","volume":"1","author":"van der Woude FJ","year":"1985","unstructured":"van der Woude FJ, Rasmussen N, Lobatto S, et al.. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985, 1:425-9. 10.1016\/s0140-6736(85)91147-x","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.09.001","article-title":"Update on the epidemiology, risk factors, and outcomes of systemic vasculitides","volume":"32","author":"Berti A","year":"2018","unstructured":"Berti A, Dejaco C. Update on the epidemiology, risk factors, and outcomes of systemic vasculitides. Best Pract Res Clin Rheumatol. 2018, 32:271-94. 10.1016\/j.berh.2018.09.001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem107","article-title":"Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden","volume":"46","author":"Mohammad AJ","year":"2007","unstructured":"Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford). 2007, 46:1329-37. 10.1093\/rheumatology\/kem107","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond C","year":"2013","unstructured":"Comarmond C, Pagnoux C, Khellaf M, et al.. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013, 65:270-81. 10.1002\/art.37721","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"30 Suppl 1","author":"Watts RA","year":"2015","unstructured":"Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Su\u00e1rez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015, 30 Suppl 1:i14-22. 10.1093\/ndt\/gfv022","journal-title":"Nephrol Dial Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13515","article-title":"The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy","volume":"202","author":"Trivioli G","year":"2020","unstructured":"Trivioli G, Vaglio A. The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy. Clin Exp Immunol. 2020, 202:403-6. 10.1111\/cei.13515","journal-title":"Clin Exp Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.926044","article-title":"The complement system and ANCA associated vasculitis in the era of anti-complement drugs","volume":"13","author":"Kimoto Y","year":"2022","unstructured":"Kimoto Y, Horiuchi T. The complement system and ANCA associated vasculitis in the era of anti-complement drugs. Front Immunol. 2022, 13:926044. 10.3389\/fimmu.2022.926044","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber A","year":"2009","unstructured":"Schreiber A, Xiao H, Jennette JC, et al.. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009, 20:289-98. 10.1681\/ASN.2008050497","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao H","year":"2014","unstructured":"Xiao H, Dairaghi DJ, Powers JP, et al.. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014, 25:225-31. 10.1681\/ASN.2013020143","journal-title":"J Am Soc Nephrol"},{"key":"ref12","unstructured":"TAVNEOS\u00ae (avacopan). (2023). Accessed. April 1, 2024: https:\/\/www.tavneospro.com\/?cid=PPC-accountype%3AGOOGLE-campaign%3ABND_HCP_Decision_Core_AAV_EXM%2BPHM_2024-searchter...."},{"key":"ref13","article-title":"Immunobiology: the immune system in health and disease","author":"Janeway CA Jr","year":"2001","unstructured":"Janeway CA Jr, Travers P, Walport M, et al.. Immunobiology: the immune system in health and disease. Garland Science, New York; 2001."},{"key":"ref14","unstructured":"Nucala (mepolizumab) for healthcare professionals. (2022). Accessed. April 1, 2024: https:\/\/nucalahcp.com\/egpa\/#:~:text=NUCALA%20is%20conditionally%20recommended%20as,Management%20of%20ANCA%2DAssociate...."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000502021","article-title":"Glucocorticoid therapy in ANCA vasculitis: using the glucocorticoid toxicity index as an outcome measure","volume":"2","author":"Floyd L","year":"2021","unstructured":"Floyd L, Morris A, Joshi M, Dhaygude A. Glucocorticoid therapy in ANCA vasculitis: using the glucocorticoid toxicity index as an outcome measure. Kidney360. 2021, 2:1002-10. 10.34067\/KID.0000502021","journal-title":"Kidney360"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad237","article-title":"ANCA-associated vasculitis-treatment standard","volume":"39","author":"Chalkia A","year":"2024","unstructured":"Chalkia A, Jayne D. ANCA-associated vasculitis-treatment standard. Nephrol Dial Transplant. 2024, 39:944-55. 10.1093\/ndt\/gfad237","journal-title":"Nephrol Dial Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith RM","year":"2020","unstructured":"Smith RM, Jones RB, Specks U, et al.. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020, 79:1243-9. 10.1136\/annrheumdis-2019-216863","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2717","article-title":"A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease (abstract)","volume":"79","author":"Smith R","year":"2020","unstructured":"Smith R, Jayne D, Merkel P. A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease (abstract). Arthritis Rheumatol. 2020, 79:19-20. 10.1136\/annrheumdis-2020-eular.2717","journal-title":"Arthritis Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin L","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, et al.. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014, 371:1771-80. 10.1056\/NEJMoa1404231","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles P","year":"2020","unstructured":"Charles P, Perrodeau \u00c9, Samson M, et al.. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020, 173:179-87. 10.7326\/M19-3827","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone JH","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363:221-32. 10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones RB","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, et al.. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010, 363:211-20. 10.1056\/NEJMoa0909169","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151063","article-title":"The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis","volume":"43","author":"Kermani TA","year":"2016","unstructured":"Kermani TA, Cuthbertson D, Carette S, et al.. The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis. J Rheumatol. 2016, 43:1078-84. 10.3899\/jrheum.151063","journal-title":"J Rheumatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne DR","year":"2021","unstructured":"Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021, 384:599-609. 10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne DR","year":"2017","unstructured":"Jayne DR, Bruchfeld AN, Harper L, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017, 28:2756-67. 10.1681\/ASN.2016111179","journal-title":"J Am Soc Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low EGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar FB","year":"2023","unstructured":"Cortazar FB, Niles JL, Jayne DR, et al.. Renal recovery for patients with ANCA-associated vasculitis and low EGFR in the ADVOCATE trial of avacopan. Kidney Int Rep. 2023, 8:860-70. 10.1016\/j.ekir.2023.01.039","journal-title":"Kidney Int Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888816","article-title":"Complement inhibition in ANCA-associated vasculitis","volume":"13","author":"Tesar V","year":"2022","unstructured":"Tesar V, Hruskova Z. Complement inhibition in ANCA-associated vasculitis. Front Immunol. 2022, 13:888816. 10.3389\/fimmu.2022.888816","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel PA","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R, et al.. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020, 2:662-71. 10.1002\/acr2.11185","journal-title":"ACR Open Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha D","year":"2024","unstructured":"Geetha D, Dua A, Yue H, Springer J, Salvarani C, Jayne D, Merkel P. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Ann Rheum Dis. 2024, 83:223-32. 10.1136\/ard-2023-224816","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler ME","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, et al.. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017, 376:1921-32. 10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.08.021","article-title":"Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis","volume":"95","author":"R\u00edos-Garc\u00e9s R","year":"2022","unstructured":"R\u00edos-Garc\u00e9s R, Prieto-Gonz\u00e1lez S, Hern\u00e1ndez-Rodr\u00edguez J, et al.. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. Eur J Intern Med. 2022, 95:61-6. 10.1016\/j.ejim.2021.08.021","journal-title":"Eur J Intern Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2020.1827417","article-title":"Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?","volume":"58","author":"Vergles M","year":"2021","unstructured":"Vergles M, Matkovi\u0107 Z, Lali\u0107 K, Trkanjec JT, Tudori\u0107 N. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?. J Asthma. 2021, 58:1675-9. 10.1080\/02770903.2020.1827417","journal-title":"J Asthma"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2020.12.5.885","article-title":"Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis","volume":"12","author":"Vultaggio A","year":"2020","unstructured":"Vultaggio A, Nencini F, Bormioli S, et al.. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. 2020, 12:885-93. 10.4168\/aair.2020.12.5.885","journal-title":"Allergy Asthma Immunol Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim S","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010, 125:1336-43. 10.1016\/j.jaci.2010.03.028","journal-title":"J Allergy Clin Immunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld J","year":"2019","unstructured":"Steinfeld J, Bradford ES, Brown J, et al.. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2019, 143:2170-7. 10.1016\/j.jaci.2018.11.041","journal-title":"J Allergy Clin Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1159\/000526410","article-title":"Effectiveness of low-dose mepolizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): a real-life experience","volume":"183","author":"\u00d6zdel \u00d6zt\u00fcrk B","year":"2022","unstructured":"\u00d6zdel \u00d6zt\u00fcrk B, Yavuz Z, Ayd\u0131n \u00d6, Mungan D, Sin BA, Demirel YS, Bavbek S. Effectiveness of low-dose mepolizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): a real-life experience. Int Arch Allergy Immunol. 2022, 183:1281-90. 10.1159\/000526410","journal-title":"Int Arch Allergy Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2024.01.007","article-title":"Monocentric study of IL-5 monoclonal antibody induction therapy for eosinophilic granulomatosis with polyangiitis","volume":"123","author":"Wang CR","year":"2024","unstructured":"Wang CR, Tsai HW, Shieh CC. Monocentric study of IL-5 monoclonal antibody induction therapy for eosinophilic granulomatosis with polyangiitis. J Formos Med Assoc. 2024, 123:802-10. 10.1016\/j.jfma.2024.01.007","journal-title":"J Formos Med Assoc"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clicom.2022.01.002","article-title":"Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"2","author":"Ramirez GA","year":"2022","unstructured":"Ramirez GA, Cariddi A, Noviello S, et al.. Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis. Clin Immunol Commun. 2022, 2:23-9. 10.1016\/j.clicom.2022.01.002","journal-title":"Clin Immunol Commun"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road109","article-title":"Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan: 48-week interim analysis of the MARS study","author":"Ishii T","year":"2023","unstructured":"Ishii T, Kunishige H, Kobayashi T, et al.. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan: 48-week interim analysis of the MARS study. Mod Rheumatol. 2023, 10.1093\/mr\/road109","journal-title":"Mod Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord ID","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012, 380:651-659. 10.1016\/S0140-6736(12)60988-X","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega HG","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, et al.. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014, 371:1198-1207. 10.1056\/NEJMoa1403290","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel EH","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014, 371:1189-1197. 10.1056\/NEJMoa1403291","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-017-1636-6","article-title":"Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives","volume":"12","author":"Manenti L","year":"2017","unstructured":"Manenti L, Urban ML, Maritati F, Galetti M, Vaglio A. Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. Intern Emerg Med. 2017, 12:727-31. 10.1007\/s11739-017-1636-6","journal-title":"Intern Emerg Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu A","year":"2023","unstructured":"Cottu A, Groh M, Desaintjean C, et al.. Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2023, 82:1580-6. 10.1136\/ard-2023-224624","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/250033-superiority-of-avacopan-and-mepolizumab-to-glucocorticoid-tapering-in-the-treatment-of-anti-neutrophil-cytoplasmic-antibody-anca-associated-vasculitis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:51:03Z","timestamp":1724050263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/250033-superiority-of-avacopan-and-mepolizumab-to-glucocorticoid-tapering-in-the-treatment-of-anti-neutrophil-cytoplasmic-antibody-anca-associated-vasculitis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.67161","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,18]]}}}